Ms Donna Reidlinger
Clinical Operations Manager
Centre for Health Services Research
Australasian Kidney Trials Network
+61 7 344 37994
Journal Articles
Gummer, Joel, Trengove, Robert, Pascoe, Elaine M., Badve, Sunil V., Cass, Alan, Clarke, Philip, McDonald, Stephen P., Morrish, Alicia T., Pedagogos, Eugenie, Perkovic, Vlado, Reidlinger, Donna, Scaria, Anish, Walker, Rowan, Vergara, Liza A., Hawley, Carmel M., Johnson, David W., Olynyk, John K. and Ferrari, Paolo (2017) Association between serum hepcidin-25 and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Nephrology, 22 7: 548-554. doi:10.1111/nep.12815
Zhang, Lei, Coombes, Jeff, Pascoe, Elaine M., Badve, Sunil V., Dalziel, Kim, Cass, Alan, Clarke, Philip, FerrarI, Paolo, McDonald, Stephen P., Morrish, Alicia T., Pedagogos, Eugenie, Perkovic, Vlado, Reidlinger, Donna, Scaria, Anish, Walker, Rowan, Vergara, Liza A., Hawley, Carmel M. and Johnson, David W. (2016) The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: sub-study of the HERO trial.. Redox Report, 21 1: 14-23. doi:10.1179/1351000215Y.0000000022
Badve, Sunil V., Zhang, Lei, Coombes, Jeff S., Pascoe, Elaine M., Cass, Alan, Clarke, Philip, Ferrari, Paolo, McDonald, Stephen P., Alicia T. Morrish, Eugenie Pedagogos, Vlado Perkovic, Donna Reidlinger, Anish Scaria, Rowan Walker, Liza A. Vergara, Carmel M. Hawley, David W. Johnson and and on behalf of the HERO Study Collaborative Group (2015) Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Canadian Journal of Kidney Health and Disease, 2 33: 1-10. doi:10.1186/s40697-015-0066-5
Johnson, David W., Pascoe, Elaine M., Badve, Sunil V., Dalziel, Kim, Cass, Alan, Clarke, Philip, Ferrari, Paolo, McDonald, Stephen P., Morrish, Alicia T., Pedagogos, Eugenie, Perkovic, Vlado, Reidlinger, Donna, Scaria, Anish, Walker, Rowan, Vergara, Liza A., Hawley, Carmel M., on behalf of the HERO Study Collaborative Group and Fassett, Rob (2015) A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the handling erythropoietin resistance with oxpentifylline (HERO) trial. American Journal of Kidney Diseases, 65 1: 49-57. doi:10.1053/j.ajkd.2014.06.020
Morrish, A.T., Hawley, C.M., Johnson, D.W., Badve, S.V., Perkovic, V., Reidlinger, D.M. and Cass, A. (2014) Establishing a clinical trials network in nephrology: Experience of the Australasian Kidney Trials Network. Kidney International, 85 1: 23-30. doi:10.1038/ki.2013.391
Conference Papers
Badve, S. V., Pascoe, E. M., Cass, A., Clarke, P., Coombes, J., Ferrari, P., Mcdonald, S. P., Morrish, A. T., Pedagogos, E., Perkovic, V., Reidlinger, D., Scaria, A., Walker, R., Vergara, L. A., Hawley, C. M. and Johnson, D. W. (2014). Association Between Serum Alkaline Phosphatase and Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: a Post-Hoc Analysis of the Hero Trial. In: Programme and Abstract Book of the 50th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology. 50th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Melbourme, VIC Australia, (32-32). 25-27 August 2014. doi:10.1111/nep.12301
Zhang, L., Pascoe, E. M., Badve, S. V., Cass, A., Clarke, P., Coombes, J. S., Ferrari, P., Mcdonald, S. P., Morrish, A. T., Pedagogos, E., Perkovic, V., Reidlinger, D., Scaria, A., Walker, R., Vergara, L. A., Hawley, C. M. and Johnson, D. W. (2014). The effect of pentoxifylline on oxidative stress markers: substudy of the hero trial. In: 50th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Melbourne, VIC, Australia, (35-35). 25-27 August 2014. doi:10.1111/nep.12301